TITLE

AMGEN SUBMITS ANEMIA THERAPY VARIATION APPLICATION TO EMEA

PUB. DATE
December 2001
SOURCE
Worldwide Biotech;Dec2001, Vol. 13 Issue 12, p1
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports the application for the expansion of the indication for Aranesp anemia therapy by Amgen to the European Agency for the Evaluation of Medicinal Products. Information on the indication sought for the darbepoetin alfa drug; Significance of the application to Amgen; Results of clinical trials for the drug.
ACCESSION #
7120982

 

Related Articles

  • New data highlight Aranesp efficacy in anemic patients with lymphoid cancer.  // PharmaWatch: Cancer;August 2003, Vol. 2 Issue 8, p19 

    Presents data highlighting the effectiveness of Amgen's Aranesp in treating anemic patients with lymphoid cancer. Data supporting the expansion of the drug's indications to include treatment of chemotherapy-induced anemia in adults with non-myeloid malignancies.

  • New anemia drug offers patients more convenience. Carrell, Steve // Drug Topics;10/15/2001, Vol. 145 Issue 20, p28 

    Discusses the treatment of chemotherapy-related anemia by darbepoetin manufactured by Amgen. Fact about darbepoetin that drives the use of the drug; Price of darbepoetin; Factor that makes the drug popular among patients who must supply a copayment for each injection.

  • Amgen case study.  // Amgen Case Study: Protecting Epogen from Competition;Apr2005, p1 

    The report examines how pharmaceutical company Amgen was able to prolong the life of its anemia products. The company used three strategies to do this and these are defending patent protection, exploiting the absence of a biogenic approval pathway and developing enhanced next generation...

  • Amgen Posts Lower Aranesp Sales.  // Bioworld Week;8/6/2007, Vol. 15 Issue 32, p2 

    The article reports on the decline of worldwide sales of Aranesp drug from Thousand Oaks, California-based Amgen Inc. as of the second quarter of 2007. According to Amgen, the 10% decrease of Aranesp worldwide sales was due to the reimbursement issues related to the anemia drug and the drop of...

  • Aranesp approved for extended dosing by in Europe.  // PharmaWatch: Biotechnology;November 2004, Vol. 3 Issue 11, p9 

    Announces that the European Commission has approved expanded marketing authorization for Aranesp, the anemia treatment of biotechnology firm Amgen, in the European Union. Extension of Aranesp dosing intervals of once-every-three-weeks in the treatment of anemia in adult cancer patients with...

  • Anemia Treatment Through the Years. Szromba, Charlotte // Nephrology Nursing Journal;Mar/Apr2009, Vol. 36 Issue 2, p229 

    The article presents an answer to a question about the type of treatment available to anemia patients before treatment with erythropoiesis-stimulating agents (ESA) was available to them.

  • Amgen's Epogen Successor Aranesp Gets FDA Approval. Krause, Carey // Chemical Market Reporter;9/24/2001, Vol. 260 Issue 11, p14 

    Reports on the approval of the U.S. Food and Drug Administration for Aranesp the successor to the anemia drug Epogen from Amgen. Forecast of financial analysts on Aranesp; Plan of Amgen to submit a biologics license supplement for Aranesp; Share of Amgen in the U.S. dialysis market.

  • Bright Prospects for Biotech's Leader. Richardson, Vanessa // Money;Aug1999, Vol. 28 Issue 8, p48 

    Discusses the improved financial outlook that biotechnology company Amgen is facing as of August 1999. How an increase in Medicare payments for Epogen, its anemia-fighting drug, will ensure a rise in the drug's revenues; Analysts' belief that Amgen will win a patent fight surrounding Epogen;...

  • Affymax Clearing Pathway For Hematide In 'Murky' ESA Space. Boggs, Jennifer // BioWorld Today;7/17/2007, Vol. 18 Issue 137, p1 

    This article reports on the decision of Affymax, Inc. to proceed with a Phase III program of its anemia drug Hematide in chronic renal failure patients. Patients on dialysis and those who are not will be enrolled by the company in four concurrent, open-label, randomized trials to evaluate the...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics